FDA Announces December 3, 20259:00 AM to 6:00 PMHold an online meeting for its Circulatory System Device Expert Committee to review the pre-market approval application of the V-Wave Ventura Atrial Shunt.Expert Committee on Circulatory System DevicesWill be based on clinical data to demonstrateV-Wave Ventura Atrial ShuntValue, and make recommendations to the FDA regarding its Pre-Market Approval (PMA) application. The FDA generally (but not always) adopts the opinions of its Medical Expert Committee.。This is a atrial shunt device which has been discussed at medical conferences and undergone clinical trials for nearly a decade.Nowadays, atrial shunt devices finally have the opportunity to be reviewed by the FDA.Expert Review, which means that the atrial分流器 is expected to receive FDA approval. Once the vote is passed, the atrial分流器 willExpected to be approved for marketing next year, which will...New Treatment Options for Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).V-Wave VenturaAn atrial分流器 is a new type of hourglass-shaped implant, itsThere is a small opening in the middle, allowing blood to flow from the left atrium to the right atrium.Thereby achieving a reduction in the elevated left-heart pressure commonly observed in patients with advanced chronic heart failure.
V-Wave VenturaThe suitable population for atrial shunt devices are patients with New York Heart Association (NYHA) Class III heart function — these patients still experience significant physical activity limitations and symptoms despite standardized medication treatment.Atrial ShuntClearly applicable to patients with left ventricular ejection fraction (LVEF) ≤40% and assessed by the cardiac team as suitable for implantation.
V-Wave VenturaAtrial shunt devices have been the subject of extensive clinical research. Although some clinical studies have failed to meet their endpoints,Patients with left ventricular ejection fraction (LVEF) ≤40% (subgroup) showed excellent results., a 45% reduction in cardiovascular events compared to the placebo group (49.0% vs. 88.6%, RR 0.55).At this year's TCT conference, its clinical data was also recognized by clinical experts.Icahn School of Medicine at Mount SinaiGregg Stone believes: "V-Wave VenturaPatients with reduced ejection fraction have clear cardiovascular benefits, with very significant effects. Not only is the risk of heart failure hospitalization reduced by 52% in HFrEF patients, but mortality also shows a positive improvement trend, while also reducing the need for advanced interventions such as heart transplantation or left ventricular assist devices (LVAD).Due toV-Wave Ventura inExcellent clinical outcomes in patients with left ventricular ejection fraction (LVEF) ≤40% led Johnson & Johnson to ultimately spend $1.7 billion (including $1.1 billion in milestone-based incentives) on the acquisition last year.V-Wave Ventura。More than one year after the acquisition, Johnson & Johnson has alreadyV-Wave Ventura Pushed for Registration. If everything goes smoothly (voted on December 3rd),V-Wave Ventura Could Be Approved for Market Entry As Early As Next Year. This Will Be a Significant Victory in the Atrial Shunt Device Field, While Also Opening Up Another Billion-Dollar Market. It Will Also Drive Johnson & Johnson's Rapid Growth in the Cardiovascular Field.This also gives a strong boost to many atrial shunt device companies participating in China.From 2022Corvia MedicalTheREDUCE LAP-HF II Clinical Trial Failure. Similar to RDN a few years ago, shifting from cold to hot.Atrial Shunt Devices Regain Capital and Clinical Favor.
